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factors; VitD3, 1,25-dihydroxyvitamin D3; NBT assay, nitroblue tetrazolium assay; RT-qPCR, quantitative reverse transcription
polymerase chain reaction; KPNA2, karyopherin a, 2; SF2A1, splicing factor 2A1; PLK1, polo-like kinase 1; RAB5C, member RAS
oncogene family 5C; RAB10, member RAS oncogene family 10; AGO2, argonaute 2; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; ECL methods, enhanced chemiluminescence methods; PMSF, phenylmethylsulfonyl fluoride; GFP, green fluorescent
protein
Treatment of leukemia cells with 1,25-dihydroxyvitamin D3 may overcome their differentiation block and lead to the
transition from myeloblasts to monocytes. To identify microRNA-mRNA networks relevant for myeloid differentiation,
we profiled the expression of mRNAs and microRNAs associated to the low- and high-density ribosomal fractions in
leukemic cells and in their differentiated monocytic counterpart. Intersection between mRNAs shifted across the
fractions after treatment with putative target genes of modulated microRNAs showed a series of molecular networks
relevant for the monocyte cell fate determination, as for example the post-transcriptional regulation of the Polo-like
kinase 1 (PLK1) by miR-22–3p and let-7e-5p.
Introduction
During hematopoiesis the cell lineage determination of hae-
matopoietic progenitor cells (HPCs) is largely controlled by a
unique combination of lineage specific transcription factors
(TFs) that regulate in a cooperative way the activity of promoters
and enhancers present on their target genes.1,2 Interestingly,
recent findings indicate that microRNAs (miRNAs) also are
involved in the regulation of the haematopoietic cell fate determi-
nation at different stages.3 For example, in human CD34CHPCs
undergoing unilineage differentiation/maturation the miR-223
overexpression favors granulocytic differentiation, whereas, the
miRNAs 17–5p-20a-106a knockdown results in a more rapid
monocytic differentiation.4,5 Moreover, it is clearly emerging
that miRNAs are integrated with transcription factors in regula-
tory circuitries involved in the decisions regarding the ability to
self-renew and to generate a differentiated progeny in haemato-
poietic cells including myeloid cells.6-9
Acute myeloid leukemia (AML) represents the clonal
expansion of haematopoietic precursors blocked at different
stages of differentiation and several evidences link the deregu-
lated miRNAs expression to the establishment of the leuke-
mic phenotype highlighting a role for miRNAs in
hematopoiesis and tumorigenesis.10 Of note, the maturation
block underlying specific AML subtypes may be efficiently
overcome in vitro and ex vivo by the treatment with physio-
logic inducers such as the active form of vitamin D, 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3] that is able to trigger
human myeloid precursors differentiation.11-13
Given the relevance of miRNAs activity in pathological hema-
topoiesis many efforts are focused to disclose the gene expression
regulatory networks established by miRNAs during the onset of
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the leukemic phenotype and the differentiation treatment of
AML.10,14,15
miRNAs are able to modulate gene expression mainly by tun-
ing the rate of proteins’ translation.16-20 Recent studies present
evidence that miRNAs may repress protein synthesis inhibiting
initiation or later stages of translation.21-25 However, it has been
also recently reported that destabilization of target mRNAs may
also be responsible for reduced protein output.26,27
Prediction algorithms usually provide hundreds of target genes
for each miRNA and the identification of reliable target genes is
feasible only through single-gene approaches. To identify relevant
miRNA targets, implicated in the differentiation of AML cells,
we here evaluated the localization of miRNAs and mRNAs in
ribosomal/polysomal cell fractions obtained by sucrose density
gradient centrifugation from the acute myeloblastic leukemia cell
line HL60 induced or not to differentiate by 1,25-dihydroxyvita-
min D3 treatment to induce monocyte/macrophage differentia-
tion.28 A change in the association of an mRNA with polysomes
is indicative of changes in its translation state. For instance, a
block in translational initiation would result in reduced ribosome
density on the affected mRNA and a shift toward the lower-den-
sity fractions of the gradient. On this basis we took advantage of
mRNA/miRNA expression information across the low- and
high-density ribosomal fractions to identify reliable target
mRNAs of miRNAs relevant for monocyte differentiation.
Results and Discussion
To identify relevant miRNAs-mRNAs functional interactions
during monocytic differentiation of AML cells, we performed
microarray analyses of the ribosome/polysome-associated miR-
NAs and mRNAs in proliferating HL60 cells and in cells induced
to differentiate by 1,25-dihydroxyvitamin D3 (VitD3) treatment.
A schematic representation of the experimental approach is pre-
sented in Figure 1A. Monocytic differentiation of HL60 cells
was assessed by CD14/CD11b surface markers analysis and by
NBT assay for the assessment of phagocytic and cytotoxic activity
(Fig. 1B).
To separate fractions with different ribosomal density, cell
lysates from HL60 cells, treated or not with VitD3 for 72 hours,
were subjected to sucrose density gradient centrifugation, obtain-
ing 11 fractions for each experimental condition (Fig. S1A). The
obtained fractions 3, 4 and 5 correspond to the 40S, 60S and
80S subunits, respectively, while fractions 6 to 11 correspond to
polysomes. RNA was extracted from each fraction and expression
profiling of miRNAs and mRNAs from fractions 3 through 11
(which enabled sufficient amplification and labeling) was per-
formed on the Agilent (Human miRNA microarray V3) and on
the Affymetrix (GeneChip Human Gene 1.0 ST Array) plat-
forms, respectively.
A subset of miRNAs shows altered ribosomal association
after monocyte differentiation
Expression profiling identified 177 miRNAs (Fig. 1C) that
were detectable in at least 2 of the analyzed fractions. miRNAs
were mainly located in low-density fractions (Fig. 2A). This
localization suggested an involvement of miRNAs mainly in
translation initiation blockage in our experimental system.
To highlight miRNAs functionally involved in translation
control during monocyte/macrophage differentiation we
searched for miRNAs whose association with ribosomal machin-
ery was affected by VitD3-mediated differentiation. As shown in
Figure 1D, we identified 9 and 22 miRNAs whose association
with ribosomal machinery was increased and decreased, respec-
tively, after VitD3 treatment (File S1). Association of 6 selected
miRNAs (let-7e-5p, miR-146a-5p, miR-378a-3p, miR-22–3p,
miR-96–5p and miR-17–5p) to the ribosomal fractions was vali-
dated by RT-qPCR analysis (Fig. 1E-J), which confirmed that
these miRNAs mainly localized to the low-density fractions,
where they are increased or decreased after monocytic differentia-
tion. Interestingly, RT-qPCR analysis of such 4 miRNAs in total
RNA preparations from HL60 cells, treated or not with VitD3,
revealed that let-7e-5p and miR-22–3p are markedly upregulated
after VitD3, miR-146a-5p is slightly upregulated, miR-378a-3p
is undetectable, while miR-96–5p and miR-17–5p are downre-
gulated (Fig. 1E-J, right graphs). This indicates that the analysis
of ribosomal fractions enables the identification of potentially rel-
evant miRNAs that wouldn’t be identified through expression
analysis on total RNA. To analyze lineage specificity of the
observed miRNA modulations, the expression level of miRNAs
that were altered in total RNA between control and VitD3
treated cells was evaluated in additional differentiation condi-
tions, as granulocytic differentiation of NB4 cells (induced by
retinoic acid), monocytic differentiation of THP-1 cells (induced
by TPA) and erythroid differentiation of K562 cells (induced by
AraC). As shown in Supplementary Figure 1B, we observed that
miR-22–3p, miR-96–5p and miR-17–5p show expression mod-
ulations that are common to both monocytic and granulocytic
differentiation.
Among the 22 miRNAs showing lower ribosome association
in differentiated cells we noticed 8 members of the miR-17–92
cluster. Down-regulation of members of miR-17–92 cluster was
previously reported in TPA- and PMA-driven monocytic differ-
entiation of AML cells.15,29 Moreover, also members of the miR-
NAs showing higher ribosome association in differentiated cells
in our results (such as for example miR-21–5p, miR-22–3p and
miR-26a-5p) were previously shown to be upregulated during
monocyte differentiation of leukemia cells.15,29-32
mRNAs belonging to monocyte/macrophage-related
functions are modulated during the VitD3-induced
differentiation of HL60 cells
The analysis of the effect of differentiation on mRNAs associ-
ation to ribosomal/polysomal fractions evidenced 967 genes with
enhanced recruitment to the ribosomal/polysomal machinery
and 545 genes with decreased recruitment after VitD3 treatment
(Fig. 2A; File S2).
To investigate whether these modulated genes were function-
ally related, we performed functional annotation clustering using
the DAVID bioinformatics database. As shown in Figure 2B and
Supplementary File 3, among the up-regulated transcripts we
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identified a significant enrichment for
genes belonging to pathways strictly
related to well-known monocyte/mac-
rophage functions, as chemokines and
cytokines signaling, phagocytosis and
various receptors signaling pathways
(Toll like-, NOD like-, and RIG-1
like- receptors). According to the
reduced proliferation that is observed
during HL60 differentiation,33 among
the down-regulated transcripts we
found a significant enrichment for cell
cycle promoting genes, such as cyclins
(B1, B2 and H), CDK6 and Bub fam-
ily genes (Bub1, Bub1b and Bub3)
(File S3).
Transcripts shifting between low- and high-density fractions
after VitD3 treatment maybe subjected to miRNAs-mediated
translation control
We reasoned that changes in the abundance of miRNAs in the
low-density fractions following the differentiation of HL60 cells
to monocytes/macrophages should result in changes of their tar-
get mRNAs abundance between low- and high-density fractions.
Specifically, we expected that an up-regulation of a miRNA, fol-
lowing VitD3 treatment, should result in the shift of its target
mRNAs to the low-density fractions, with consequent transla-
tional repression; on the contrary, a downregulation of a miRNA
should result in a shift of its target mRNAs to the high-density
Figure 1. Expression profiles of miRNAs in
the ribosomal/polysomal fractions of HL60
cells treated or not with VitD3 for 72h. (A).
Schematic representation of the experi-
mental approach. mRNA and miRNA
expression profiles were obtained from
RNA associated to high- and low-density
ribosomal fractions in HL60 cells treated
with VitD3 (HL60 VitD3) or control
untreated cells (HL60 CTR). mRNAs that
were shifted from high- to low-density
fractions and vice versa after VitD3 treat-
ment were considered for subsequent
intersection analysis with the list of genes
putatively targeted by VitD3-modulated
miRNAs to identify miRNA-mRNA interac-
tions. (B). HL60 were treated (HL60 VitD3)
or not (HL60 CTR) for 72h with VitD3 to
induce monocytic differentiation. FACS
analysis of cells positively stained for
CD11b and CD14 myeloid surface markers
(upper panel) and a light microscopy rep-
resentative field showing the NBT dye
reduction assay (lower panel) are shown.
(C). Expression profile of the 177 detect-
able miRNAs in ribosomal/polysomal frac-
tions from HL60 cells treated or not with
VitD3 for 72 h. (D). Expression profile of 22
and 9 miRNAs respectively down- and up-
regulated by treatment of HL60 cells with
VitD3 for 72 h. (E-J). RT-qPCR analysis of 6
selected miRNAs, let-7e-5p, miR-22–3p,
miR-146a-5p, miR-378a-3p, miR-96–5p
and miR-17–5p, in ribosomal/polysomal
fractions from HL60 cells treated or not
with VitD3 for 72 h. Each graph on the
right shows RT-qPCR analysis of that
miRNA in total RNA from HL60 cells
treated or not with VitD3 for 72 h.
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Figure 2. Expression profiles of mRNAs in the ribosomal/polysomal fractions of HL60 cells treated or not with VitD 3 for 72h. (A). Expression matrix repre-
senting the distribution across low- and high-density ribosomal fractions of mRNAs significantly modulated following VitD3 treatment of HL60 cells.
(B). Functional annotation analysis of genes modulated during differentiation of HL60 cells. Pathways with p-value <0.02 and containing >10 genes
were selected.
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fractions, with consequent loosening of the translational repres-
sion. On this rational basis we first sought if there were mRNAs
that moved from high- to low- density fractions and vice versa
following VitD3 treatment. We thus identified 473 transcripts
that were shifted from high- to low- density fractions following
treatment (hereafter indicated as “slowed-down” mRNAs) and
301 transcripts that behaved in opposite manner (hereafter indi-
cated as “speeded-up” mRNAs). A score indicating the strength
of shifting between high- and low- density fractions was assigned
to each of these transcripts (Table 1; File S2).
Functional annotation analysis of these speeded-up (SU) and
slowed-down (SD) mRNAs is reported in Figure 3A and Sup-
plementary File 4. SU mRNAs belong to processes, such as for
example “transport through vesicles” and “protein localization,”
which were not enriched in the increased genes shown in
Figure 1B; on the contrary, SD mRNAs were enriched for genes
belonging to processes also found in the decreased genes shown
in Figure 1B (for example “cell cycle” and “splicing”).
We validated by RT-qPCR the distribution of some of
these transcripts among the ribosomal fractions. As shown in
Figures 3B-D, we observed a shift of the mRNAs encoding
KPNA2, SF2A1 and PLK1 from the high-density to the low-
density fractions following treatment with VitD3. On the
contrary RAB5C and RAB10 mRNAs behaved in opposite
manner, shifting from the low-density to the high-density
fractions after VitD3 (Fig. 3E; Fig. S2A).
Table 1.miRNAs predicted to target the top 20 ranked speeded-up and slowed-down mRNAs
top 20 ranked speeded-up mRNAs
Symbol Gene Name Score miRNA
MLF2 myeloid leukemia factor 2 9,58 miR-125b-5p (2)
SRI sorcin 8,53 miR-590–5p, miR-630, miR-18a-5p, miR-20a-5p, miR-18b-5p
RAB10 RAB10, member RAS oncogene family 7,83 miR-20b-5p, miR-20a-5p, miR-17–5p, miR-96–5p
POLR2K polymerase (RNA) II polypeptide K 7,78 miR-101–3p
TRAPPC1 trafficking protein particle complex 1 7,73 miR-96–5p
INSIG2 insulin induced gene 2 7,54 miR-19a-3p, miR-20b-5p, miR-92a-3p, miR-19b-3p, miR-17–5p, miR-96–5p
DPY30 dpy-30 homolog (C. elegans) 7,47 miR-101–3p
POMP proteasome maturation protein 6,88 miR-101–3p
PAIP2 poly(A) binding protein interacting protein 2 6,76 miR-29b-3p (3), miR-29c-3p (2), miR-96–5p
TAF12 (TBP)-associated factor, 20kDa 6,76 miR-96–5p
AP1S1 adaptor-related protein complex 1, sigma 1 subunit 6,75 miR-29b-3p, miR-29c-3p
NR1H2 nuclear receptor subfamily 1, group H, member 2 6,74 miR-18a-5p, miR-18b-5p
CFL1 cofilin 1 6,72 miR-96–5p
UBE2A ubiquitin-conjugating enzyme E2A 6,68 miR-101–3p, miR-19a-3p (3), miR-19b-3p (6)
RAB5C RAB5C, member RAS oncogene family 6,66 miR-18a-5p (2), miR-18b-5p (2)
CDC42SE2 CDC42 small effector 2 6,63 miR-20b-5p, miR-18a-5p, miR-20a-5p, miR-18b-5p
ANAPC13 anaphase promoting complex subunit 13 6,59 miR-92a-3p
DAD1 defender against cell death 1 6,52 miR-19a-3p, miR-19b-3p
NDFIP1 Nedd4 family interacting protein 1 6,48 miR-101–3p (2), miR-19a-3p, miR-19b-3p, miR-18a-5p, miR-18b-5p
TMEM50A transmembrane protein 50A 6,31 miR-125b-5p, miR-92a-3p
top 20 ranked slowed-down mRNAs
Symbol Gene Name Score miRNA
KPNA2 karyopherin a 2 9,55 miR-26a-5p (2)
PLK1 Polo-like kinase 1 9,33 miR-22–3p, let7e-5p (2), miR-9–3p
RBM22 RNA binding motif protein 22 8,22 miR-21–5p
DPF2 D4, zinc and double PHD fingers family 2 7,92 miR-125a-5p, miR-22–3p, let7e-5p
DLST dihydrolipoamide S-succinyltransferase 7,65 let7e-5p
FLII flightless I homolog (Drosophila) 7,47 miR-125a-5p, miR-378a-3p
PES1 pescadillo homolog 1 (zebrafish) 7,39 miR-125a-5p
EFTUD2 elongation factor Tu GTP binding domain containing 2 7,36 miR-26a-5p
NMT1 N-myristoyltransferase 1 7,07 miR-125a-5p
NUSAP1 nucleolar and spindle associated protein 1 6,93 miR-22–3p
ARFGAP2 ADP-ribosylation factor GTPase activating protein 2 6,84 miR-125a-5p, miR-22–3p
DDX24 DEAD (Asp-Glu-Ala-Asp) box helicase 24 6,83 miR-22–3p
CTPS CTP synthase 1 6,79 miR-125a-5p, let7e-5p
DPP3 dipeptidyl-peptidase 3 6,49 miR-146a-5p, let7e-5p
METTL3 methyltransferase like 3 6,46 miR-21–5p
GTPBP1 GTP binding protein 1 6,42 miR-125a-5p, miR-21–5p
ADRBK2 adrenergic, b, receptor kinase 2 6,37 miR-146a-5p, miR-26a-5p, miR-125a-5p, miR-378a-3p
GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial 6,33 miR-378a-3p
NT5DC1 5’-nucleotidase domain containing 1 6,08 miR-26a-5p, miR-125a-5p, miR-378a-3p
SF3A1 splicing factor 3a 6,08 miR-26a-5p
Numbers in parenthesis, when present, indicate the number of sites for a given miRNA on target mRNA.
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Speeded-up and slowed-down transcripts are good candidates
for miRNA-mediated translation control and were used for sub-
sequent analysis.
We generated lists of putative predicted targets for each of the
miRNAs altered between proliferating and differentiated HL60
cells (Fig. 1D). mRNAs that were predicted to be targeted by
Figure 3. VitD3 treatment leads to the shift of a group of mRNAs between high- and low-density fractions. (A). Functional annotation analysis of the
speeded-up and slowed-down mRNAs during differentiation of HL60 cells. The most statistically significant biological processes are shown. (B). RT-qPCR
analysis of KPNA2, SF2A1, PLK1 and RAB5C was performed on low- and high-density fractions from HL60 cells treated or not with VitD3 for 72h. Gene
expression was normalized over 18S rRNA.
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a given miRNA by at least 3 out of 10 considered prediction
algorithms were included in each list.
We intersected the list of slowed-down mRNAs with that
of putative target mRNAs of upregulated miRNAs and the list
of speeded-up mRNAs with that of putative target mRNAs of
downregulated miRNAs. Results for the top 20 ranked speeded-
up and slowed-down genes and the miRNAs predicted to target
them are reported in Table 1. Results for all intersections are
enclosed in the Supplementary Files 5 and 6.
We next evaluated effects of miRNAs modulation on protein
expression of shifted mRNAs. Specifically, inhibition of miR-
96–5p and miR-17–5p activity by transfection of LNA oligonu-
cleotides resulted in increased expression of RAB10 protein,
whose transcript was speeded-up upon differentiation and pre-
dicted to be targeted by these miRNAs (Fig. S2A).
While examining the shifted transcripts, our attention was
particularly captured by PLK1, a major mitotic regulator, which
is emerging as an attractive therapeutic target in AML.34 PLK1
has indeed been reported to be strongly up-regulated in the
majority of AML patients and, in recent years, several PLK1
inhibitors have been developed, with Volasertib showing the
most promising results in early-phase clinical trials.34,35
According to the increased PLK1 mRNA in low-density frac-
tions following differentiation, we observed that PLK1 protein
level decreased in HL60 cells after VitD3 treatment (Fig. 4A).
Similar results were observed in the U937 cell line treated with
VitD3 (Fig. 4B).
To evaluate whether this was a miRNA-dependent down-reg-
ulation, we analyzed PLK1 protein levels in HL60 cells depleted
or not of Argonaute-2 (Ago-2) protein. Argonaute-2 is the main
mediator of the translation inhibitory activity of miRNAs and we
previously reported that Ago-2 expression is necessary for VitD3-
driven monocytic differentiation.13 As shown in Figure 4C, the
downregulation of PLK1 protein occurring after VitD3 treatment
is lost in cells depleted of Ago-2, indicating the requirement of
miRNAs activity for PLK1 translation control during monocytic
differentiation.
As reported in Table 1, PLK1 mRNA is predicted to be tar-
geted by 3 of the miRNAs that we found increased after differen-
tiation (e.g. miR-22–3p, let-7e-5p and miR-9–3p). Functional
correlation analysis of the miRNAs that were upregulated after
VitD3 treatment, performed using DIANA miRPath V2.0 web-
server,36 evidenced that, of the 3 miRNAs predicted to target
PLK1, miR-22–3p and let-7e-5p were the most strictly related
(Fig. 4D). Base pairing of PLK1 mRNA with miR-22–3p or let-
7e-5p is shown in Figure 4E. We next evaluated whether modu-
lation of expression of these miRNAs affected PLK1 expression.
To this end we transfected miR-22–3p mimic, let-7e-5p mimic
or control mimic in U937 cells, showing high basal levels of
PLK1, and we analyzed PLK1 protein expression during differen-
tiation. As shown in Figure 4F and Supplementary Figure 2C,
miR-22–3p and let-7e-5p over-expression resulted in down-regu-
lation of PLK1 protein expression in untreated cells (left panel)
and after VitD3 treatment (middle and right panels). Analysis of
PLK1 mRNA levels in the same experimental conditions further
supports post-transcriptional regulation of PLK1 by miR-22–3p
and let-7e-5p (Fig. 4G). As miR-22–3p is predicted to target
PLK1 through a sequence located internally to the protein coding
region (CDS) we evaluated whether miR-22–3p mimic transduc-
tion was able to down-regulate an exogenously expressed PLK1
transcript lacking 5’-UTR and 3’-UTR. As shown in Figure 4H,
miR-22–3p mimic transduction decreases endogenous (left
panel) as well as exogenous GFP-tagged (right panel) PLK1
expression to an extent similar to that observed upon VitD3
treatment.
Altogether these results demonstrate that the co-localization of
miRNAs and predicted target mRNAs in low-density ribosomal
fractions is strongly indicative of their functional interaction.
The identification of new molecular players involved in mye-
loid cell fate determination paves the way for the identification of
new potentially interesting molecular targets for the treatment of
acute myeloid leukemia.
Materials and Methods
Cell culture and proliferation/differentiation assay
HL60, NB4, THP-1 and K562 cell lines were maintained in
RPMI 1640 medium supplemented with 1 £ penicillin/strepto-
mycin solution, 1 £ L-glutamine and 10% Fetal Bovine Serum.
Cell proliferation and differentiation were evaluated and quanti-
fied by direct cell counting (trypan blue dye exclusion method)
using a hemocytometer chamber, by NBT dye reduction assay
and by direct immunofluorescence analysis for the evaluation of
the CD11b-CD14 co-expression as a marker of monocytic differ-
entiation, as previously described.13
Reagents
1,25-dihydroxyvitamin D3 (VitD3) was purchased from
Sigma-Aldrich (St. Louis, MO, USA) and utilized at a concentra-
tion of 250 ng/ml.
Western blot analysis
30 mg of whole-cell extract were separated by 4–12% SDS-
PAGE (Invitrogen) and electroblotted to nitrocellulose mem-
brane (Protran, Whatman S&S, Maidstone, UK). Mouse mono-
clonal anti-PLK1 (Abcam, #17057), anti-Tubulin (Sigma-
Aldrich), anti-GAPDH (Sigma-Aldrich) and rabbit polyclonal
anti-b-Actin (Cell Signaling), anti-GFP (Santa Cruz Biotechnol-
ogy, sc-9996) and anti-Rab 10 (Cell Signaling, #4262) were
used. Western blot analysis was performed with the aid of the
enhanced chemiluminescence system (Thermo Fisher Scientific,
Rockford, IL, USA). ECL detection was done using a UVITEC
Alliance 4.7 (Cambridge, UK) instrument.
Polysome analysis and fractionation
Polyribosome preparation and polysome analysis were essen-
tially performed as previously described.37 Briefly, 30 £ 106 cells
were washed with ice cold PBS and resuspended in 300 ml of ice-
cold Lysis Buffer (10 mM Tris-HCl [pH 7.5], 50 mM KCl,
10 mM MgCl2, 0.1% NP-40, 15 U/ml RNaseOUT, 1 mM
PMSF and 1 mg/ml Aprotinin, 1 mg/ml Leupeptin), incubated
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Figure 4. For figure legend, see page 698.
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for 10 min on ice and centrifuged at 4C for 10 min at
13.000 rpm. The supernatant was collected, layered on a linear
15 to 50% sucrose gradient prepared in 10 mM Tris-HCl
[pH 7.5], 50 mM KCl, 10 mM MgCl2 and centrifuged at 4
C
in a SW41 Beckman rotor for 2h at 37.000 rpm. The gradient
was scanned at A254 by using the BioLogic system (Bio-Rad)
with a flow rate of 1.25 ml/min and fractionated by using the
2110 gradient collector (Bio-Rad) with a fix size of 0.8 ml/frac-
tion. From each fraction the RNA sample was extracted by using
TRIzol RNA Isolation Reagent (Invitrogen, Carlsbad, CA,
USA).
Ago2 Silencing by Lentiviral shRNA
The shRNA expression cassette for AGO2 silencing was subcl-
oned to generate the lentiviral vector pRRLsin.PPT.shAGO2.
hPGK.EGFP.WP and the infective particles were produced and
utilized as previously described.13
Cells transfection and treatment
3£105 cells/ml were transfected with mirVana mimic
(Ambion) negative control or let7e-5 p or miR-22–3 p, and miR-
CURY LNATM microRNA negative control or miR-96–5 p or
miR-17–5 p inhibitors (Exiqon) at final concentration of 5nM in
a 6-well plate using TransIT-X2 Dynamic Delivery System
(Mirus) according to the manufacturer’s instructions. Twenty-
four hours after transfection, cells were treated with 250 ng/ml
of VitD3 and harvested at 48 h and 72 h of treatment.
RNA extraction and RT-qPCR
Total RNA for microarray analyses was extracted using Trizol
(Invitrogen, Carlsbad, CA, USA) from fractions obtained by
sucrose density gradient centrifugation. Genomic DNA contami-
nation was eliminated through a DNase I (Qiagen, Chatsworth,
CA) digestion step. RNA was further purified on Qiagen RNeasy
columns for gene expression profiling (Qiagen, Chatsworth,
CA). The concentration and purity of total RNA were assessed
using a Nanodrop TM 1000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA). Reverse transcription
was performed with SuperScript II (Invitrogen). Quantification
of miRNAs was carried out with TaqMan MicroRNA Assays
(Applied Biosystems) normalizing over endogenous RNU44
snRNA. RT-qPCR was carried out on ABI PRISM 7500
Sequence Detection System (Applied Biosystems, Carlsbad, CA,
USA) using assays listed in Supplementary Table 1. Expression
values of mRNAs were calculated by standard curve method and
normalized over 18S rRNA.
Expression profiling of miRNAs
Total RNA (100 ng) was labeled and hybridized to Human
miRNA microarray V3 (Agilent). Scanning and image analysis
were performed using the Agilent DNA Microarray Scanner
(P/N G2565BA). Feature Extraction Software (Version 10.5)
was used for data extraction from raw microarray image files
using the miRNA_105_Dec08 FE protocol. miRNAs were called
present if at least 2 of the fractions presented values over the cut-
off (set at 5). miRNA expression values were considered modu-
lated when their expression was changed more than 2 folds in
fractions F3 and F4 after VitD3 treatment. Expression values
were standardized, so that the expression of each miRNA has
mean 0 and standard deviation 1. miRNA expression values are
deposited in GEO database with accession number GSE67837.
Lists of miRNAs predicted targets were generated by using the
miRWalk website (http://www.umm.uni-heidelberg.de/apps/
zmf/mirwalk). mRNAs predicted to be targeted by at least 3 out
of 10 prediction algorithms were considered. For miRNAs not
included in all prediction algorithms databases, all available pro-
grams were used.
Hierarchical clustering of miRNAs and pathways based on the
levels of their interactions was performed using the DIANA miR-
Path V2.0 web-server.36
Expression profiling of mRNAs
Expression profiles were determined by using the Human Gene
1.0 ST arrays (Affymetrix) according to the manufacturer’s instruc-
tions as previously described.38 Scanned image files (.CEL) were
processed, normalized (RMA-Sketch Quantile) and Log2-trans-
formed by Expression Console Software (Affymetrix website).
Transcripts presenting values higher than 6 in at least 3 out of the
18 fractions were considered for further analyses. A supervised
comparison analysis was performed by using the Analyzer software
in order to select significantly modulated genes.39 Hierarchical
cluster analysis was performed using CTWC algorithm (http://
ctwc.weizmann.ac.il/ctwc.htlm). mRNA expression values are
deposited in GEO database with accession number GSE67837.
Definition of the score for slowed-down and speeded-up mRNAs
To identify transcripts shifted between the low- and high-den-
sity ribosomal fractions following VitD3 treatment, expression
signals were processes using MATLAB (The MathWorks Inc..) in
house-built routines. Specifically, we selected transcripts satisfying
the following conditions: (sum(D(:,1:4)-C(:,1:4),2)>1. and sum
(D(:,6:9)-C(:,6:9),2)<-1.) i.e. the subtraction of the sum of the
values of the fractions 1–4 from the untreated sample from the
Figure 4. (See previous page). PLK1 is down-regulated at translation level during monocyte differentiation. (A-B). Western blot analysis of PLK1 protein
in HL60 (A) and U937 (B) cells treated or not with VitD3 for the indicated times. (C). Western blot analysis of PLK1 protein in control and Ago2-depleted
HL60 cells in presence/absence of VitD3 treatment (left panel). RT-qPCR analysis of Ago-2 mRNA in control and Ago2-depleted HL60 cells is shown in
right panel. (D). miRNA cluster dendrogram showing the functional correlation analysis of the miRNAs that were upregulated after VitD3 treatment. Anal-
ysis was performed using DIANA miRPath V2.0 software. (E). Base pairing between PLK1 mRNA and miR-22–3p or let-7e-5p. (F). Western blot analysis of
PLK1 protein in U937 cells transfected with let-7e-5p mimic (indicated with 7e), miR-22–3p mimic (indicated with 22) or control mimic (indicated with C),
after 48h and 72 h of VitD3 treatment (upper panels). (G). PLK1 mRNA levels from experiment shown in (G), evaluated by RT-qPCR. (H). Western blot anal-
ysis of endogenous (left panel) and exogenous GFP-tagged (right panel) PLK1 proteins in untreated U937 cells transfected with miR-22–3p mimic (indi-
cated with 22) or control mimic (indicated with C), and in VitD3-treated U937 (indicated with VitD3).
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sum of the VitD3-treated fractions 1–4, must be greater than 1;
moreover, the subtraction of the sum of the values of the frac-
tions 6–9 from the untreated sample from the sum of the VitD3-
treated fractions 6–9, must be lower than ¡1. To transcripts that
meet this condition we assigned a score defined as follows:
Score=(sum(D(:,1:4)-D(:,6:9),2) C sum(C(:,6:9)-C(:,1:4),2))
Gene Ontology
Enriched KEGG pathways and biological processes were iden-
tified by using the DAVID bioinformatic tool (http://david.abcc.
ncifcrf.gov/home.jsp).
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